Improving the response to hepatitis B vaccine

Infections in Medicine

Volumn 16, Issue 3, 1999, Pages 205-210

  Rosman, Alan S ^a,b   Lieber, Charles S ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Hepatitis B virus (HBV); Immunization; Liver disease; Renal failure; Vaccines

Indexed keywords

HEPATITIS B VACCINE;

ALCOHOLISM; CHRONIC KIDNEY FAILURE; HEPATITIS B; HUMAN; IMMUNE RESPONSE; IMMUNOSTIMULATION; REVIEW; TREATMENT FAILURE; VACCINATION;

EID: 0033049421     PISSN: 07496524     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Katkov WN: Hepatitis vaccines. Med Clin North Am 80:1189-1200, 1996.
2. Engerix-B Package Insert. Physicians' Desk Reference. Oradell, NJ, Medical Economics, 1998.
3. Recombivax HB Package Insert. Physicians' Desk Reference. Oradell, NJ, Medical Economics, 1998.
4. Johnson DW, Fleming SJ: The use of vaccines in renal failure. Clin Pharmacokinet 22:434-446, 1992.
5. Maupas P, Goudeau A, Coursaget P, et al: Hepatitis B vaccine: Efficacy in high-risk settings - A two-year study. Intervirology 10:196-208, 1978.
6. Crosnier J, Jungers P, Courouce AM, et al: Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: II, Haemodialysis patients. Lancet 1:797-800, 1981.
7. Crosnier J, Jungers P, Courouce AM, et al: Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: I, Medical staff. Lancet 1:455-459, 1981.
8. Stevens CE, Alter HJ, Taylor PE, et al: Hepatitis B vaccine in patients receiving hemodialysis: Immunogenicity and efficacy. N Engl J Med 311:496-501, 1984.
9. Bergamini F, Zanetti AR, Ferroni P, et al: Immune response to hepatitis B vaccine in staff and patients in renal dialysis units. J Infect 7(suppl 1):S35-S40, 1983.
10. Grob PJ, Binswanger U, Zaruba K, et al: Immunogenicity of a hepatitis B subunit vaccine in hemodialysis and in renal transplant recipients. Antiviral Res 3:43-52, 1983.
11. Kohler H, Arnold W, Renschin G, et al: Active hepatitis B vaccination of dialysis patients and medical staff. Kidney Int 25:124-128, 1984.
12. de Graeff PA, Dankert J, de Zeeuw D, et al: Immune response to two different hepatitis B vaccines in haemodialysis patients: A 2-year follow-up. Nephron 40:155-160, 1985.
13. Jilg W, Schmidt M, Weinel B, et al: Immunogenicity of recombinant hepatitis B vaccine in dialysis patients. J Hepatol 3:190-195, 1986.
14. Pasko MT, Bartholomew WR, Beam TJ, et al: Long-term evaluation of the hepatitis B vaccine (Heptavax-B) in hemodialysis patients. Am J Kidney Dis 11:326-331, 1988.
15. El-Reshaid K, Al-Mufti S, Johny KV, et al: Comparison of two immunization schedules with recombinant hepatitis B vaccine and natural immunity acquired by hepatitis B infection in dialysis patients. Vaccine 12:223-234, 1994.
16. Benhamou E, Courouce AM, Jungers P, et al: Hepatitis B vaccine: Randomized trial of immunogenicity in hemodialysis patients. Clin Nephrol 21:143-147, 1984.
17. Aronoff GR, Maxwell DR, Batteiger BE, et al: Hepatitis B virus vaccine: A randomized trial of a reduced dose regimen in hemodialysis patients. Am J Kidney Dis 6:170-172, 1985.
18. Lelie PN, Reesink HW, de Jong-van Manen ST, et al: Immune response to a heat-inactivated hepatitis B vaccine in patients undergoing hemodialysis: Enhancement of the response by increasing the dose of hepatitis B surface antigen from 3 to 27 micrograms. Arch Intern Med 145:305-309, 1985.
19. Seaworth B, Drucker J, Starling J, et al: Hepatitis B vaccines in patients with chronic renal failure before dialysis. J Infect Dis 157:332-337, 1988.
20. Bruguera M, Cremades M, Rodicio JL, et al: Immunogenicity of a yeast-derived hepatitis B vaccine in hemodialysis patients. Am J Med 87(suppl 3A):S30-S32, 1989.
21. Mitwalli A: Responsiveness to hepatitis B vaccine in immunocompromised patients by doubling the dose scheduling. Nephron 73:417-420, 1996.
22. Fleming SJ, Moran DM, Cooksley WG, et al: Poor response to a recombinant hepatitis B vaccine in dialysis patients. J Infect 22:251-257, 1991.
23. Buti M, Viladomiu L, Jardi R, et al: Long-term immunogenicity and efficacy of hepatitis B vaccine in hemodialysis patients. Am J Nephrol 12:144-147, 1992.
24. Docci D, Cipolloni PA, Mengozzi S, et al: Immunogenicity of a recombinant hepatitis B vaccine in hemodialysis patients: A two-year follow-up. Nephron 61:352-353, 1992.
25. Chang PC, Schrander-van der Meer AM, van Dorp WT, et al: Intracutaneous versus intramuscular hepatitis B vaccination in primary non-responding haemodialysis patients. Nephrol Dial Transplant 11:191-193, 1996.
26. Mauri JM, Valles M: Effects of recombinant interleukin-2 and revaccination for hepatitis B in previously vaccinated, non-responder, chronic uraemic patients. Collaborative Group of Girona. Nephrol Dial Transplant 12:729-732, 1997.
27. Fabrizi F, Andrulli S, Bacchini G, et al: Intradermal versus intramuscular hepatitis b re-vaccination in non-responsive chronic dialysis patients: A prospective randomized study with cost-effectiveness evaluation. Nephrol Dial Transplant 12:1204-1211, 1997.
28. Dukes CS, Street AC, Starling JF, et al: Hepatitis B vaccination and booster in predialysis patients: A 4-year analysis. Vaccine 11:1229-1232, 1993.
29. Oddone EZ, Cowper PA, Hamilton JD, et al: A cost-effectiveness analysis of hepatitis B vaccine in predialysis patients. Health Serv Res 28:97-121, 1993.
30. Meuer SC, Dumann H, Meyer zum Buschenfelde KH, et al: Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet 1:15-18, 1989.
31. Immunization Practices Advisory Committee: Hepatitis B virus: A comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. MMWR 40(RR-13):1-25, 1991.
32. Paronetto F: Immunologic reactions in alcoholic liver disease, in Lieber CS (ed): Medical and Nutritional Complications of Alcoholism: Mechanisms and Management. New York, Plenum Publishing Co., 1992, pp 283-305.
33. Mendenhall C, Roselle GA, Lybecker LA, et al: Hepatitis B vaccination: Response of alcoholics with and without liver injury. Dig Dis Sci 33:263-269, 1988.
34. Nalpas B, Thepot V, Driss F, et al: Secondary immune response to hepatitis B virus vaccine in alcoholics. Alcohol Clin Exp Res 17:295-298, 1993.
35. Villanueva C, Enriquez J, Just J, et al: Vaccination against the hepatitis B virus in alcoholics. Med Clin (Barc) 96:211-214, 1991.
36. Rosman AS, Basu P, Galvin K, et al: Efficacy of a high and accelerated dose of hepatitis B vaccine in alcoholic patients: A randomized clinical trial. Am J Med 103:217-222, 1997.
37. Degos F, Duhamel G, Brechot C, et al: Hepatitis B vaccination in chronic alcoholics. J Hepatol 2:402-409, 1986.
38. Craven DE, Awdeh ZL, Kunches LM, et al: Nonresponsiveness to hepatitis B vaccine in health care workers: Results of revaccination and genetic typings. Ann Intern Med 105:356-360, 1986.
39. Struve J, Aronsson B, Frenning B, et al: Seroconversion after additional vaccine doses to non-responders to three doses of intradermally or intramuscularly administered recombinant hepatitis B vaccine. Scand J Infect Dis 26:468-470, 1994.
40. Chiaramonte M, Ngatchu T, Majori S, et al: Response to an extra dose of hepatitis B vaccine and specific antibody persistence in non-responders to primary immunization. Scand J Gastroenterol 30:601-603, 1995.
41. Clemens R, Sanger R, Kruppenbacher J, et al: Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule - Results of a post-marketing surveillance. Vaccine 15:349-352, 1997.
42. Goldwater PN: Randomized, comparative trial of 20 micrograms vs 40 micrograms Engerix-B vaccine in hepatitis B vaccine non-responders. Vaccine 15:353-356, 1997.
43. Bertino JS, Tirrell P, Greenberg RN, et al: A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, preS1, and pre-S2 particles for revaccination of healthy adult nonresponders. J Infect Dis 175:678-681, 1997.